Vimarsana
Biggest News Aggregation in the World

Biotech Ceo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biotech Ceo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biotech Ceo Today - Breaking & Trending Today

BioTech Company CEO Spends Millions to Reverse his Age; Claims to Reduce 5.1 Years in 7 Months - Vimarsana News

BioTech Company CEO Spends Millions to Reverse his Age; Claims to Reduce 5.1 Years in 7 Months

BioTech company founder and CEO Bryan Johnson has been spending millions to reduce his age via sophisticated technology. His biotech company is running a project named ‘BluePrint’ that aims to alter the epigenetic constitution of humans, for which Johnson is also a part of the trials.

Source: india.com
Seagen CEO Clay Siegall. steps aside amid domestic violence allegations - Vimarsana News

Seagen CEO Clay Siegall. steps aside amid domestic violence allegations

Seagen’s co-founder Clay Siegall, Ph.D., has been put on a leave of absence after an alleged incident of domestic violence that happened at his home.

Fierce Pharma Asia—Legend CEO's cell therapy ambitions; Indian pharmas' awkward position; new Hutchmed CEO - Vimarsana News

Fierce Pharma Asia—Legend CEO's cell therapy ambitions; Indian pharmas' awkward position; new Hutchmed CEO

After its first commercial launch in Carvykti, Legend Biotech's CEO talked up the rising CAR-T star's cell therapy ambitions.

Moderna CEO's pay jumps 41% to $18.2M as COVID vaccine giant expands globally - Vimarsana News

Moderna CEO's pay jumps 41% to $18.2M as COVID vaccine giant expands globally

Moderna’s business took flight in 2021 thanks to authorizations for its COVID-19 vaccine, and so did its CEO’s pay.

With J&J-partnered CAR-T nod in hand, Legend CEO eyes earlier myeloma use, cheaper cell therapy manufacturing - Vimarsana News

With J&J-partnered CAR-T nod in hand, Legend CEO eyes earlier myeloma use, cheaper cell therapy manufacturing

Nearly five years after unveiling the first clinical data for its BCMA-targeted CAR-T therapy, Legend Biotech has transitioned into a commercial company with an FDA approval for Carvykti and Johnso